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Abstract 
Neuropathic pain can arise from lesions to peripheral or central nerve fibres leading to spontaneous 
action potential generation and a lowering of the nociceptive threshold. Clinically, neuropathic pain 
can manifest in many chronic disease states such as cancer, diabetes or multiple sclerosis (MS). The 
bioactive lipid, lysophosphatidic acid (LPA), via activation of its receptors (LPARs), is thought to 
play a central role in both triggering and maintaining neuropathic pain. In particular, following an 
acute nerve injury, the excitatory neurotransmitters glutamate and substance P are released from 
primary afferent neurons leading to upregulated synthesis of lysophosphatidylcholine (LPC), the 
precursor for LPA production. LPC is converted to LPA by autotaxin (ATX), which can then 
activate macrophages/microglia and modulate neuronal functioning. A ubiquitous feature of animal 
models of neuropathic pain is demyelination of damaged nerves. It is thought that LPA contributes to 
demyelination through several different mechanisms. Firstly, high levels of LPA are produced 
following macrophage/microglial activation that triggers a self-sustaining feed-forward loop of de 
novo LPA synthesis. Secondly, macrophage/microglial activation contributes to inflammation-
mediated demyelination of axons, thus initiating neuropathic pain. Therefore, targeting LPA 
production and/or the family of LPA-activated G protein-coupled receptors (GPCRs) may prove to 
be fruitful clinical approaches to treating demyelination and the accompanying neuropathic pain. 
This review discusses our current understanding of the role of LPA/LPAR signalling in the initiation 
of neuropathic pain and suggests potential targeted strategies for its treatment. 
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1. Neuropathic pain 
According to the International Association for the Study of Pain (IASP), neuropathic pain (NP) is 
defined as the pain caused by a lesion to, or a disease of, the somatosensory nervous system. In other 
words, NP is a complex, chronic pain state resulting from damage to neural tissue such as peripheral 
afferent neurons, dorsal root ganglia (DRG) or spinal cord neurons. It can also result from direct 
damage to peripheral and central neurons, which often occur in cancer (Zhao et al., 2010), traumatic 
brain injury (TBI) (Crack et al., 2014) or multiple sclerosis (MS) (Khan and Smith, 2014). 
Characteristic symptoms of NP include unpleasant abnormal sensations (dysaesthesia), an enhanced 
perception of pain in response to noxious stimuli (hyperalgesia), as well as abnormal painful 
responses to innocuous or tactile stimuli that do not usually cause pain (allodynia) (Frisca et al., 
2012; Fujita et al., 2007). While the mechanisms underlying allodynia are still partially unknown, 
neuropathic hyperalgesia is associated with up-regulation of molecules, such as substance P and the 
excitatory neurotransmitter glutamate, which enhance the transmission of painful stimuli in DRG and 
spinal dorsal horn neurons (Fujita et al., 2007; Marchand et al., 2005; Ueda, 2006). 
 
Based on a review of studies published since 2000, it is estimated that 7% of the world’s population 
is affected by NP (Andrew et al., 2014). However, an epidemiological review of chronic pain found 
that, within a given population, there are still no accurate estimates available for the prevalence of 
NP (Smith and Torrance, 2012). Although many investigations into the underlying mechanisms of 
NP have uncovered perturbations to both peripheral nerves and to spinal cord neurons, most 
experimental therapeutics tested for their ability to correct distorted pain perception, target peripheral 
neuron damage. Various types of noxious stimuli, mechanical, chemical or thermal in nature, can 
activate nociceptors on unmyelinated C-fibres and thinly-myelinated Aδ-fibres leading to increases 
in ectopic electrical discharges and lowering of the nociceptive threshold. Localised accumulation of 
voltage-gated ion channels, in particular sodium (Na+) channels, is responsible for this 
hyperexcitability (Aurilio et al., 2008; Casals-Diaz et al., 2015). In addition, upregulation of the 
transient receptor potential cation channel subfamily V member 1 (TRPV1) can also sensitise C-
fibres to heat by lowering the nociceptive threshold to under 41oC (Ma et al., 2005). Similar damage-
induced hyperexcitability of DRG neurons can also result in NP (Aurilio et al., 2008; Baron, 2006; 
Baron et al., 2010; Chung and Chung, 2002). In the central nervous system, sensitisation of injured 
neurons can manifest from molecular perturbations such as phosphorylation of postsynaptic NMDA- 
and AMPA-type glutamate receptors (Katano et al., 2011; Wang et al., 2014) and activation of 
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signalling cascades such as extracellular signal-regulated kinase (ERK) pathways (Zhang et al., 
2014). Loss of inhibitory GABAergic interneurons and/or reduced GABA release in the spinal cord 
can also culminate in neuronal hyperexcitability (Moore et al., 2002). Finally, inflammation plays a 
significant role in sensitising peripheral and CNS neurons following nerve injury (Moalem et al., 
2005). 
 
Since NP is a multifactorial disorder affecting both the peripheral nervous system (PNS) and CNS, it 
is not surprising that the current therapies for NP are largely inadequate and that combination 
therapies, which target several distinct pathways, may be needed in future. As pain transmission is 
known to be modulated by excitatory and inhibitory neurotransmitters, as well as calcium (Ca2+) and 
Na+ channels, many of the currently available treatments target these systems. Among currently-
approved first-line treatments for NP are the antidepressants Duloxetine and Desipramine and the 
anticonvulsants Gabapentin and Pregabalin (NICE, 2015). The first two drugs are approved 
antidepressants and their analgesia-promoting effects may be directly related to their ability to 
prevent presynaptic reuptake of serotonin and noradrenaline, both of which inhibit descending pain 
pathways in the CNS (Sawynok et al., 2001). Desipramine is a tricyclic antidepressant categorized as 
a secondary amine with relatively selective inhibition of noradrenaline reuptake (Maizels and 
McCarberg, 2005). Duloxetine is a potent and selective serotonin–noradrenaline reuptake inhibitor 
(SNRI) and lacks affinity for other neurotransmitters (Bymaster et al., 2001). Interestingly, neither 
Paroxetine (serotonin reuptake inhibitor) nor Thionisoxetine (noradrenaline reuptake inhibitor) 
displayed efficacy in attenuating pain-related behaviours in mice. However, combining both drugs 
effectively alleviated pain (Iyengar et al., 2004) suggesting that the likely mechanism of action of 
antidepressants in reducing chronic pain is mediated through inhibition of both serotonin and 
noradrenaline reuptake. In contrast, the anticonvulsants Gabapentin and Pregabalin, bind to α2δ1-
containing voltage-gated calcium (Ca2+) channels (VGCC) on central terminals of primary afferent 
nociceptors, leading to decreased release of the excitatory neurotransmitters noradrenaline, glutamate 
and substance P (Baron et al., 2010; Xu et al., 2012). Second-line treatments for NP usually include 
selective serotonin reuptake inhibitors (SSRIs) or anticonvulsants in combination with opioids, 
botulinum toxin type A or lidocaine (NICE, 2015). A major disadvantage of currently-approved 
therapeutics for NP is that they usually need to be taken chronically. To date, there is no 
pharmacological therapy available which acts to reverse and cure the underlying molecular 
mechanisms that cause the pathological state that gives rise to NP.  
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1.1. Animal models of neuropathic pain 
There are more than 40 clinically-relevant animal models of neuropathic pain (Jaggi et al., 2011). 
Many of these are peripheral nerve injury models such as the neuroma model which mimics 
anaesthesia dolorosa, i.e. a constant burning or aching pain in an area which is otherwise devoid of 
sensory input (i.e. numb) (Wall et al., 1979); chronic constriction injury (CCI) which models 
hypersensitivity to non-noxious stimuli and chemical irritants (Bennett and Xie, 1988; Martucci et 
al., 2008; Sacerdote et al., 2008); the Seltzer model, also known as partial sciatic nerve ligation 
(PSNL), which induces behavioural alterations including cold allodynia, chemical hypersensitivity 
and mechanical hyperalgesia and is said to be a good model of causalgiform pain syndromes (i.e. 
severe burning pain in a limb) (Kim et al., 1997; Malmberg and Basbaum, 1998; Seltzer et al., 1990); 
and the spared nerve injury (SNI) paradigm in which the sural nerve is ‘spared’ and the tibial and 
common peroneal nerves are axotomized, thus producing thermal and mechanical hyperalgesia but, 
more importantly, facilitates the assessment of nociception in non-injured areas of skin located 
adjacent to denervated zones (Bourquin et al., 2006; Decosterd and Woolf, 2000; Shields et al., 
2003). There are also central pain models, such as the Allen’s model of contusive spinal cord injury 
(SCI) in which a weight is dropped on the exposed spinal cord leading to severe paraplegia and 
complete segmental necrosis (Allen, 1911; Greenberg et al., 1978); drug-induced neuropathy models, 
for example, the chemotherapeutic cisplatin which is known to cause peripheral axonal neuropathy 
that affects both small and large diameter sensory fibres (Cece et al., 1995; Meijer et al., 1999; 
Shimoyama et al., 2002; Tredici et al., 1999); disease-induced neuropathy models such as diabetes 
and cancer NP models (Courteix et al., 1993; Lee et al., 1990; Shimoyama et al., 2002); and various 
other in vivo models of NP (Dina et al., 2006; Imamura et al., 1997). The major limitation of current 
NP animal models is the inherent difficulty in attempting to translate improvements in animal 
behaviour to clinically-significant alleviation of human pain perception; but despite this, many of 
these models are accepted as useful tools. However, since NP can manifest in many different ways 
and has multiple aetiologies, a range of experimental animal models is needed to study the 
underlying causes of NP.  
 
Animal models of NP have facilitated the identification of disrupted cellular processes at peripheral, 
spinal and cerebral cortical levels. In the periphery, sensitisation occurs due to increased excitability 
and decreased firing thresholds for nociceptor terminals, as well as the release of inflammatory 
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mediators such as bradykinin and prostaglandin E2 (PGE2) (Basbaum et al., 2009; Bridges et al., 
2001; Xu et al., 2012). At the level of the central spinal cord, excitatory transmission at C-fibre 
synapses is often potentiated and the firing threshold of dorsal horn neurons is decreased. These 
phenomena can be caused by the upregulation of AMPA-type glutamate receptors and 
phosphorylation of several other ion channels leading to postsynaptic hyperexcitability (Ikeda et al., 
2006; Latremoliere and Woolf, 2009; Sandkühler, 2007). Other aspects of NP involve somatosensory 
processing, which occurs in cerebral cortical areas, such as the anterior cingulate cortex (ACC), 
where protein kinase M zeta (PKMζ) is activated, excitatory neurotransmission at pyramidal neurons 
is potentiated (LTP), glutamate receptors are upregulated and decreases in long-term depression 
(LTD) lead to disinhibition and reorganization of neural networks (Li et al., 2010; Vogt, 2005; Wu et 
al., 2005). NP, therefore, can be viewed as a spectrum of disorders with mechanistically-related, but 
distinct, aetiologies. A better understanding of the causative mechanisms of NP will be necessary in 
order to develop new therapeutic strategies for this illness. The following sections focus on the 
emerging role that lysophosphatidic acid (LPA) plays in triggering and perpetuating molecular and 
cellular disturbances associated with NP. 
 
2. Lysophosphatidic acid (LPA) signalling 
Several studies suggest that increased levels of LPA may contribute to injury-induced demyelination 
of neurons and can thus cause neuropathic pain. LPA (1-acyl-2-sn-glycerol-3-phosphate) is a well-
characterised glycerophospholipid with a molecular weight of approximately 430–480 Dalton (Yung 
et al., 2014). LPA activates a family of six distinct G protein-coupled receptors (GPCRs), named 
LPAR1-6 (Callaerts-Vegh et al., 2012) and these GPCRs signal through four distinct Gα protein 
subtypes (Gi, Gq, G12 and Gs) leading to multiple downstream signalling pathways and cellular 
responses (Frisca et al., 2012; Lin et al., 2010). In addition, LPA can also bind to the intracellular 
peroxisome proliferator-activated receptor γ (PPARγ) (McIntyre et al., 2003) and the TRPV1 cation 
channel (Nieto-Posadas et al., 2012), thus playing important roles in gene regulation and nociception, 
respectively.  
 
LPA is generated by a number of different enzymes such as phospholipases A1 and A2, 
monoacylglycerol kinase, glycerol-3-phosphate acyltransferase and autotaxin (ATX) (Noguchi et al., 
2009; Pebay et al., 2007) from various precursors including phosphatidic acid, glycerol-3-phosphate 
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and several glycerophospholipids. LPA can be produced by platelets (Eichholtz et al., 1993), 
fibroblasts (Fukami and Takenawa, 1992), mitotic neurons (Fukushima et al., 2000), astrocytes 
(Savaskan et al., 2007) and also cancer cells (Zhao et al., 2010). High concentrations of LPA have 
been observed in several pathological conditions such as atherosclerosis (Smyth et al., 2014), 
traumatic brain injury (Crack et al., 2014), spinal cord injury (Santos-Nogueira et al., 2015), different 
types of cancer (Eder et al., 2000; Lee and Yun, 2010; Zeng et al., 2009; Zhao et al., 2010), 
neuropsychiatric disorders (Yung et al., 2014) and neuropathic pain (Ahn et al., 2009; Fujita et al., 
2007). Production of LPA during inflammation promotes wound-healing and acts to control the pro-
inflammatory environment. Thus, LPA has pleiotropic effects on a wide range of cell and tissue 
types, including those located within both PNS and CNS and participates in normal physiological 
functions including cellular development, proliferation and migration (Frisca et al., 2012). Below, we 
discuss the role of high levels of LPA in the initiation, maintenance and pathophysiological 
underpinnings of NP and highlight potential therapeutic targets for its treatment. 
 
2.1. Initiation of neuropathic pain by LPA 
The role of LPA in the initiation of neuropathic pain is gaining acceptance, but the origin of raised 
LPA levels is less well established. Normal concentrations of LPA in most cell types are relatively 
low, but detectable levels (0.1 – 1 µM) have been measured in plasma, serum, saliva, cerebrospinal 
fluid (CSF) and inflammatory exudates (Frisca et al., 2012). Precursors for LPA include membrane 
phosphatidylcholines (PC) which can be converted to lysophosphatidylcholine (LPC) by the 
cytosolic phospholipase A2 (cPLA2) or calcium-independent PLA2 (iPLA2). Interestingly, inhibition 
of both enzymes abolishes nerve injury-induced LPA production (Ma et al., 2010). LPC, in turn, can 
be converted into LPA by the enzymatic action of ATX, a secreted enzyme present in the 
extracellular milieu (see Figure 1) (Tokumura et al., 2002). Notably, the CSF contains high 
concentrations (0.4 – 1.3 mg/L) of ATX (Nakamura et al., 2009). Leakage of serum containing LPA 
into the CNS can occur following injury and damage to the blood-spinal cord barrier and this rise in 
LPA levels in the CSF can trigger signalling events in neurons which culminate in neuropathic pain 
(Kusaka et al., 1998). Whilst full ATX-/- knockout mice die early in embryogenesis, heterozygous 
ATX mutant mice (ATX+/-) reportedly show a 50% decrease in ATX activity resulting in lower levels 
of LPA production and better recovery from NP (Inoue et al., 2008a; Inoue et al., 2008b; Inoue et al., 
2008c). Therefore, ATX activity leads to an increase of LPA levels in pathological states and this 
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contributes to the initiation of NP. As such, ATX is an interesting therapeutic target, upstream of 
LPA, for the treatment of NP (see Table 1). 
 
LPA-mediated signalling via Gα12/13 and activation of the signalling pathways involving RhoA, Rho-
kinase, ROCK and Ras appear to be involved in NP (Inoue et al., 2004; Radeff-Huang et al., 2004; 
Ueda, 2006). Inhibition of Rho signalling pathways by Clostridium botulinum C3 exoenzyme 
(BoTXC3) or the antagonist Y-27632 (see Table 1), prior to peripheral nerve injury, blocks 
hyperalgesia and nociceptive responses in mice (Ahn et al., 2009; Inoue et al., 2004; Inoue et al., 
2006). Confirmation that the RhoA pathway is activated through LPAR1 subtype was demonstrated 
utilising Lpar1-/- knock-out mice, which do not exhibit nociceptive responses or sensitivity after LPA 
injections (Inoue et al., 2006). Furthermore, several studies showed that intrathecal administration of 
LPA mimics partial sciatic nerve injury in mice (Inoue et al., 2004; Inoue et al., 2006; Ueda, 2006) 
whereas a related lipid, sphingosine 1-phosphate (S1P), does not produce such allodynia (Ishii et al., 
2004), thus highlighting the specificity of LPA. The observation that neuropathic pain can be 
attenuated by prophylactic treatments which block Rho signalling or LPAR activation (see Table 1) 
when they are administered pre- but not post-injury (Inoue et al., 2004) suggests that LPAR 
activation may trigger demyelination and initiate NP. 
 
It has recently been shown that both intrathecal injection of LPA into the healthy CNS and increases 
in endogenous LPA levels, caused by contusive spinal cord injury, trigger demyelination of central 
neurons (Santos-Nogueira et al., 2015). Similarly, LPA can induce demyelination in the PNS (DRG 
and trigeminal nerves) (Ahn et al., 2009; Fujita et al., 2007; Inoue et al., 2004; Ogawa et al., 2012; 
Xie et al., 2010). Both Schwann cells and oligodendrocytes express high levels of LPAR1 both in 
vivo and in vitro (Weiner and Chun, 1999) but express relatively low levels of other LPARs 
suggesting that LPA exerts its main effects on myelin-forming cell types exclusively via LPAR1 
activation. Decreases in myelin basic protein (MBP) and peripheral myelin protein 22 (PMP22) 
expressions after LPA injection in the dorsal root have also been reported and these effects were 
inhibited by pre-treating mice with BoTXC3 (Fujita et al., 2007; Inoue et al., 2004). Furthermore, 
blockade of LPAR1 and LPAR3 by diacylglycerol pyrophosphate (DGPP) or inhibition of Rho 
kinase-activated signalling pathways by Y-27632, prevented demyelination of the trigeminal nerve 
after intratrigeminal ganglionic injection of LPA (Ahn et al., 2009). Taken together, these studies 
suggest that demyelination observed on peripheral neurons due to nerve injury occurs through a 
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direct action of LPA on Schwann cells via LPAR1 (see Figure 2). In support of these findings, a 
recent study has shown that selective blockade of LPAR1, using the antagonist AM095, attenuates 
CNS demyelination after contusive spinal cord injury in mice and improves locomotor recovery 
(Santos-Nogueira et al., 2015). In addition to demyelination, LPAR1 mediates the upregulation of the 
α2δ1 Ca2+ channel subunit and the γ-isoform of protein kinase C (PKCγ) in spinal cord (Inoue et al., 
2004); both of which are well-established markers of NP (Luo et al., 2002; Weiner and Chun, 1999; 
Weiner et al., 2001). 
 
Further evidence implicating LPA signalling in NP include a report that thermal hyperalgesia and 
mechanical allodynia after PSNL are attenuated in Lpar1-/- knockout mice or by pre-treatment with 
antisense oligodeoxynucleotides against LPAR1; but because no significant changes in uninjured 
Lpar1-/- mice were observed, it was suggested that de novo LPA produced after the injury was 
responsible for initiating NP (Inoue et al., 2004). LPA also activates PLC via the Gαq/11 and Gαi/o 
coupled LPAR3 subtype. Notably, there is minimal LPA production in Lpar1-/- and Lpar3-/- mice and 
NP is abolished in this phenotype (Ma et al., 2013; Ma et al., 2009b), suggesting that both receptors 
mediate the amplification of LPA production, which is necessary to induce NP. Supporting these 
findings are reports that the chemotherapeutic drug, paclitaxel, triggers NP in mice by stimulating 
LPAR1- and LPAR3-mediated LPA production (Uchida et al., 2014). 
 
The LPAR5 subtype also plays a key role in triggering NP. Previously known as GPR92 (Lee et al., 
2006), LPAR5 is expressed on the cell bodies of C-fibres within the DRG. In contrast, LPAR5 is not 
found on Aβ fibres which transmit sensations induced by innocuous tactile stimuli (Kinloch and Cox, 
2005). Lpar5-/- mice subjected to the CCI model of NP display attenuated cold-induced allodynia 
using the acetone test, despite no changes in mechanical allodynia and spontaneous displays of 
discomfort using the von Frey test and balance box, respectively (Callaerts-Vegh et al., 2012). Lpar5-
/-
 mice also display marked protection against development of NP in the PSNL model (Lin et al., 
2012). In this study, there were no differences in sciatic nerve or DRG demyelination, or in 
expression of the NP markers, PKCγ and Ca2+ channel subunit α2δ1. In addition, the downstream 
transcriptional target of LPAR5, i.e. cAMP response element-binding protein (CREB), displayed 
lower levels of phosphorylation in Lpar5-/- mice subjected to the PSNL and CCI models of NP. 
These results suggest that LPAR5 can trigger NP by a different mechanism to LPAR1, thereby 
representing and additional drug target for the treatment of NP. 
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LPA synthesis can also be activated through other mechanisms including the pain-inducing 
neurotransmitters, glutamate and substance P, which are released from primary afferent fibres in 
response to nerve injury and activate NMDA and neurokinin-1 (NK1) receptors, respectively (Ueda 
et al., 2013). Blockade of both NMDA and NK1 receptors prior to nerve injury by their respective 
antagonists, MK-801 and CP-99994, resulted in the inhibition of LPA production at the dorsal horn 
(Ma et al., 2013). This suggests that nerve injury results in glutamate and substance P-mediated 
activation of NMDA and NK1 receptors on neurons and subsequent activation of the enzyme PLA2 
leading to LPA production and initiation of neuropathic pain (see Figure 2). 
 
2.2. Effects of LPA on non-neuronal cell types 
The induction of neuropathic pain by LPA not only relies on its actions on neurons, Schwann cells 
and oligodendrocytes, but also through its effects on other cell types such as astrocytes, 
macrophages/microglia and immune cells (Goldshmit et al., 2012; Ma et al., 2010; Smith et al., 
1999; Ueda, 2011). LPA has been shown to increase inflammation and glial cell proliferation in 
zebrafish and inhibit neural regeneration after traumatic injury (Goldshmit et al., 2012). LPA causes 
an increase in expression of brain-derived neurotrophic factor (BDNF) in primary cultures of rat 
microglia which express LPAR3 (Fujita et al., 2008). LPA activates macrophages/microglia, possibly 
through LPAR1 and LPAR3, and this initiates a self-sustaining feedforward loop of LPA production 
within macrophages/microglia, which can be inhibited with minocycline (Ma et al., 2013; Uchida et 
al., 2014). Moreover, intrathecal injection of mice with LPA increases the transcription of genes such 
as CD11b, leading to activation of microglia and morphological changes from ramified to amoeboid 
phenotypes. While early treatment with minocycline inhibits microglial activation and attenuates 
neuropathic pain, administering minocycline at later time-points has no effect (Ma et al., 2010), 
suggesting that microglia are involved to a greater extent in the initiation of NP more than in its 
maintenance. 
 
3. Recent developments in the treatment of neuropathic pain 
Because NP is a multifactorial pathological state with several distinct triggers and mechanisms 
involved in its maintenance, a personalised medicines approach to treating patients with NP will 
likely be needed to achieve optimal analgesia. There are several approaches to consider when testing 
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potential therapies for NP that target LPA/LPAR signalling. Upstream interventions may include 
targeting high levels of LPA, produced following nerve injury, by neutralising antibody-based 
therapies that act as molecular sponges (Crack et al., 2014; Goldshmit et al., 2012). In this regard, the 
humanized monoclonal antibody, anti-LPA B3, that targets LPA, is currently under investigation 
(Crack et al., 2014; Goldshmit et al., 2012). An alternative approach may be to target the enzyme 
ATX (Gierse et al., 2010; Gupte et al., 2011; Hwang et al., 2013), which contributes to LPA 
production. There are currently several ATX inhibitors in pre-clinical studies, although none are 
exclusive for NP. PF-8380 is a specific inhibitor that reduces inflammatory hyperalgesia in rats 
within 3h (Gierse et al., 2010). Other ATX inhibitors, such as 4PBPA (Gupte et al., 2011), Gintonin 
(Hwang et al., 2013) and ONO-8430506 (Benesch et al., 2014) are indicated for cancer, although 
they may also have effects on NP (see Table 1). The first oral therapy developed for MS, i.e. 
fingolimod (Kappos et al. 2006), may also act as an inhibitor of ATX (van Meeteren et al., 2008). 
 
Downstream interventions for the treatment of NP may include targeting LPARs with specific 
antagonists. There are a number of LPAR1 antagonists in early pre-clinical phase studies, such as 
AM095 (Castelino et al., 2011), Ki16425 (Liao et al., 2013; Ma et al., 2009a), BMS compounds 
(Nogueira, 2013) and VPC12249 (Okusa et al., 2003). Only the BMS compounds are specifically 
indicated for neuropathic pain (Nogueira, 2013), where, for example, BMS-986202 is in phase I and 
BMS-986020 in phase II clinical trials (Bradford, 2012). Blockade of the Rho kinase pathways is 
also a potential therapeutic strategy for NP since administration of the Rho kinase inhibitors H-1152 
or Y-27632, alleviates neuropathic pain in mice and rats (Ramer et al., 2004; Tatsumi et al., 2005). 
 
Finally, peptide-based therapeutics such as GsMTx4, a component of the Grammostola spatulata 
tarantula venom, which blocks several mechanically-activated (MA) cation channels involved in the 
transmission of pain-related signals, has shown positive results in alleviating mechanical 
hyperalgesia and NP (Park et al., 2008). Interestingly, LPA has been shown to sensitise MA channels 
in a dose-dependent manner. Epithelial and smooth muscle cells exposed to LPA display a marked 
increase in Ca2+ influx through MA channels in response to mechanical stress, but no sensitising 
effects on Ca2+ release from intracellular stores were observed in the presence of LPA (Ohata et al., 
1995; Ohata et al., 1996; Ohata et al., 1997a). This enhancement of MA channel responses by LPA 
can be attenuated by phospholipase C (PLC) inhibitors (Ohata H et al., 1997b), suggesting that it 
may be an indirect effect through activation of LPAR-mediated GPCR signalling. Therefore, 
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developing treatments for NP that block mechanically-activated ion channels on neurons and/or glial 
cell types may also inhibit the downstream sensitising effects of LPA and alleviate symptoms such as 
hyperalgesia and allodynia. 
 
4. Conclusion 
LPA is a highly bioactive molecule with a number of cellular sources and exerts its actions through a 
range of GPCRs and ion channels present on various cell types. Here, we have highlighted the role 
that LPA plays in the initiation of NP which is a diverse spectrum of disorders affecting millions of 
people worldwide for which there appears little bona fide treatment to date. There are multiple 
molecular mechanisms underlying the pathophysiology of NP thus increasing the complexity of 
developing effective targeted therapeutics. Nevertheless, it appears that LPA production and 
signalling plays a major role in the initiation of NP, exerting downstream effects on many cell types 
including neurons, Schwann cells, oligodendrocytes, macrophages, microglia, astrocytes and other 
immune cells. Therefore, targeting the production of LPA by inhibition of ATX, the enzyme 
primarily responsible for its synthesis, or blocking LPAR1 and/or LPAR5 activation and downstream 
signalling cascades could prove to be fruitful strategies to alleviate NP. Taken together, the 
LPA/LPAR signalling pathway provides multiple targets for the development of new therapeutics for 
NP and related pathologies as evidenced by recent pre-clinical, phase I and phase II studies.  
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Figure Legends 
 
Figure 1: Synthesis of lysophosphatidic acid (LPA). Precursors of LPA synthesis include 
phosphatidylcholine (PC) which is converted to lysophosphatidylcholine (LPC) by the enzymatic 
actions of cytosolic phospholipase A2 (cPLA2) and calcium-independent phospholipase A2 (iPLA2). 
LPC, in turn, is converted to LPA by autotaxin (ATX); a secreted enzyme present at relatively high 
concentrations in extracellular fluids. 
 
Figure 2: Potential mechanisms of neuropathic pain initiation by LPA. Traumatic nerve injury 
can cause the release of glutamate and substance P from peripheral neurons leading to NMDA and 
NK1 receptor activation, respectively. This can lead to influx of extracellular Ca2+ through NMDA 
receptors and activation of phospholipase A2 (cPLA2). PLA2 can also be activated in a non-calcium 
dependent manner (iPLA2) through NK1-mediated G-protein signalling. c/iPLA2 converts 
phosphatidylcholine (PC) to lysophosphatidylcholine (LPC) and this, in turn, is enzymatically 
processed into LPA via the actions of extracellular autotaxin (ATX). LPA can activate 
macrophages/microglial cell types where it signals through LPAR3 to initiate self-sustaining 
feedforward production of LPA via the enzymatic activity of c/iPLA2 and ATX. Macrophage-
derived LPA can also activate LPAR1 on myelinating Schwann cells leading to demyelination 
through various mechanisms, including down-regulation of myelin basic protein (MBP) and 
peripheral myelin protein 22 (PMP22) as well as upregulation of protein kinase C-γ (PKCγ) and the 
voltage-gated Ca2+ channel subunit α2δ1. 
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2014) 
Reference 
 
Anti-LPA B3 
 
Antibody 
LPA signalling Pre-clinical 
 
(Crack et al., 
2014) 
(Goldshmit et 
al., 2012) 
 
PF-8380 
 
 
 
ATX inhibitor Pre-clinical 
 
 
(Gierse et al., 
2010) 
 
4PBPA 
 
 
 
ATX inhibitor Pre-clinical 
 
(Gupte et al., 
2011) 
Gintonin 
 
Glycolipoprotein 
 
 
 
ATX inhibitor Pre-clinical 
 
(Hwang et al., 
2013) 
ONO-
8430506 
 
 
 
ATX inhibitor Pre-clinical 
 
(Benesch et 
al., 2014) 
BrB-LPA 
 
 
 
Dual LPAR 
antagonist/ATX 
inhibitor 
Pre-clinical 
(Xu et al., 
2009) 
 
AM095 
 
 
 
 
LPAR1 
antagonist 
Pre-clinical 
 
(Castelino et 
al., 2011) 
AM966 
 
LPAR1 
antagonist Pre-clinical 
 
(Swaney et al., 
2010) 
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KI-16425 
 
 
 
 
 
LPAR1 
antagonist 
 
Pre-clinical 
 
(Liao et al., 
2013) 
(Ma et al., 
2009a) 
BMS 
compound 
 
 
 
LPAR1 
antagonist Pre-clinical 
 
(Nogueira, 
2013) 
VPC-12249 
 
 
 
LPAR1 
antagonist Pre-clinical 
 
(Okusa et al., 
2003) 
 
BMS-
986202/AM15
2 
See patent WO/2012/162592 A1 
for more details 
LPAR1 
antagonists 
Phase I-Idiopathic 
Pulmonary Fibrosis 
 
(Bradford, 
2012) 
(BMS, 2011) 
 
BMS-986020 See patent WO/2012/162592 A1 for more details 
LPAR1 
antagonist 
 
Phase II- Idiopathic 
Pulmonary Fibrosis- 
(NCT01766817) 
 
Phase II- Systemic 
sclerosis 
(NCT02588625) 
 
 
(Bradford, 
2012) 
SAR 100842 
 
See patent WO/2012/162592 A1 
for more information 
 
LPAR1 LPAR3 
antagonist  
 
Phase II- Systemic 
sclerosis 
(NCT01651143) 
 
 
(Sanofi, 2014) 
 
H-1152 
  
Rho kinase 
inhibitor 
 
Pre-clinical 
 
(Tatsumi et 
al., 2005) 
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Y-27632 
 
 
 
Rho kinase 
inhibitor Pre-clinical 
 
(Ramer et al., 
2004) 
 
 
Table 1: LPA signalling and LPA receptor inhibitors with potential efficacy in neuropathic pain 
treatment. 
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Highlights 
 Neuropathic pain (NP) is a multifactorial pathological state with no cure. 
 Increased LPA synthesis after nerve injury can trigger demyelination, causing NP.  
 LPA/LPAR signalling contributes to maintenance of NP. 
 New therapeutics targeting LPA production and signalling may be effective in alleviating NP. 
